JP2025509520A5 - - Google Patents
Info
- Publication number
- JP2025509520A5 JP2025509520A5 JP2024554664A JP2024554664A JP2025509520A5 JP 2025509520 A5 JP2025509520 A5 JP 2025509520A5 JP 2024554664 A JP2024554664 A JP 2024554664A JP 2024554664 A JP2024554664 A JP 2024554664A JP 2025509520 A5 JP2025509520 A5 JP 2025509520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nrg
- fusion protein
- recombinant fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319886P | 2022-03-15 | 2022-03-15 | |
| US63/319,886 | 2022-03-15 | ||
| US202263385705P | 2022-12-01 | 2022-12-01 | |
| US63/385,705 | 2022-12-01 | ||
| PCT/US2023/064314 WO2023178086A1 (en) | 2022-03-15 | 2023-03-14 | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509520A JP2025509520A (ja) | 2025-04-11 |
| JP2025509520A5 true JP2025509520A5 (enExample) | 2026-03-24 |
Family
ID=86185362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554664A Pending JP2025509520A (ja) | 2022-03-15 | 2023-03-14 | ニューレグリン－１融合タンパク質による線維症及び不整脈の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250228917A1 (enExample) |
| EP (1) | EP4493580A1 (enExample) |
| JP (1) | JP2025509520A (enExample) |
| AU (1) | AU2023233680A1 (enExample) |
| CA (1) | CA3245956A1 (enExample) |
| TW (1) | TW202400217A (enExample) |
| WO (1) | WO2023178086A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025245112A1 (en) | 2024-05-21 | 2025-11-27 | Salubris Biotherapeutics, Inc. | Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN101310766B (zh) * | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| WO2017053794A1 (en) * | 2015-09-25 | 2017-03-30 | Sawyer Douglas B | Methods for treating cardiac injury |
| FI3774859T3 (fi) * | 2018-04-11 | 2024-05-24 | Salubris Biotherapeutics Inc | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät |
-
2023
- 2023-03-14 AU AU2023233680A patent/AU2023233680A1/en active Pending
- 2023-03-14 JP JP2024554664A patent/JP2025509520A/ja active Pending
- 2023-03-14 TW TW112109408A patent/TW202400217A/zh unknown
- 2023-03-14 CA CA3245956A patent/CA3245956A1/en active Pending
- 2023-03-14 EP EP23719602.7A patent/EP4493580A1/en active Pending
- 2023-03-14 WO PCT/US2023/064314 patent/WO2023178086A1/en not_active Ceased
- 2023-03-14 US US18/845,216 patent/US20250228917A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101553243B (zh) | 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体 | |
| JP2025137626A5 (enExample) | ||
| CN100424175C (zh) | ErbB-3 用于肿瘤治疗的方法和组合物 | |
| JP2021535727A5 (enExample) | ||
| US7795215B2 (en) | MNTF peptides and compositions and methods of use | |
| FI3774859T3 (fi) | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät | |
| JP2005139203A (ja) | インシュリン様成長因子（ｉｇｆ）ｉ変異体 | |
| JP2000511042A (ja) | Ｉｌ−１３受容体特異的キメラタンパク質およびその用途 | |
| WO2016118577A1 (en) | Thymosin-beta-four fusion proteins | |
| JP2009525762A (ja) | 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法 | |
| KR20080022539A (ko) | 키메라 단백질 | |
| US10456451B2 (en) | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2025509520A5 (enExample) | ||
| JP2026041880A (ja) | 細胞透過性ペプチド変異体およびその用途 | |
| US20150299280A1 (en) | Medical treatment use of cell-membrane-permeable fibroblast growth factor | |
| JP3908165B2 (ja) | 多発性硬化症の治療におけるケモカイン変異体 | |
| CN111499762A (zh) | 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途 | |
| JP2024526820A5 (enExample) | ||
| WO2023143464A1 (en) | Fusion protein and application thereof | |
| JP2001506849A (ja) | 骨刺激因子 | |
| CN109265533B (zh) | 一种改进的能与pd-1特异性结合的肿瘤抑制肽及其用途 | |
| CN115605218A (zh) | 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物 | |
| US20260092091A1 (en) | Cxc receptor ligands | |
| CN111574590A (zh) | 一种具有抗肿瘤功能的多肽及其应用 | |
| JP2008509888A (ja) | 上皮成長因子受容体アンタゴニストおよび使用方法 |